Author Correction: Porous microneedle patch with sustained delivery of extracellular vesicles mitigates severe spinal cord injury

Nature Communications, 2023 · DOI: https://doi.org/10.1038/s41467-023-40368-w · Published: July 7, 2023

Simple Explanation

This is an author correction to the original article regarding the effect of MN-EV and MN-MSC treatments on inflammatory response in spinal cord lesions after SCI. The correction clarifies that MN-MSC treatment, not MN-EV treatment, resulted in a statistically significant increase in the anti-inflammatory cytokine TGF-β, as well as increased arginase-2 and decreased IL-1β expression. The original article incorrectly stated that MN-EV treatment led to these changes, which has been corrected in both the PDF and HTML versions of the article.

Study Duration

Not specified

Participants

Not specified

Evidence Level

Not specified

Key Findings

1
The correction clarifies that MN-MSC treatment, not MN-EV treatment, resulted in a statistically significant increase in the anti-inflammatory cytokine TGF-β.
2
MN-MSC treatment also led to increased arginase-2 expression in spinal cord lesions after SCI.
3
MN-MSC treatment resulted in decreased IL-1β expression in spinal cord lesions after SCI.

Research Summary

This author correction addresses an error in the original article concerning the effects of MN-EV and MN-MSC treatments on the inflammatory response in spinal cord lesions following SCI. The correction specifies that MN-MSC treatment, rather than MN-EV treatment, caused a significant increase in the anti-inflammatory cytokine TGF-β, along with increased arginase-2 and decreased IL-1β expression. The error has been rectified in both the PDF and HTML versions of the original article.

Practical Implications

Accuracy of Scientific Findings

Ensures the accuracy and reliability of scientific findings related to the treatment of spinal cord injuries.

Impact on Future Research

Corrects a key detail that could influence the direction of future research and development in spinal cord injury therapies.

Clinical Applications

Provides clarity for potential clinical applications by accurately attributing the therapeutic effects to the correct treatment.

Study Limitations

1
The correction focuses solely on the specific error related to MN-EV and MN-MSC treatments.
2
The correction does not address other potential limitations of the original study.
3
The information provided is limited to the corrected statement and does not include details about the experimental design or broader conclusions.

Your Feedback

Was this summary helpful?

Back to Spinal Cord Injury